+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Vaccines Market - Global Forecast 2026-2032- Product Image
Cancer Vaccines Market - Global Forecast 2026-2032- Product Image
Sale

Cancer Vaccines Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010630
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Vaccines Market is projected to reach USD 11.55 Billion in 2026. It is expected to continue growing at a CAGR of 10.66%, reaching USD 21.28 Billion by 2032.

Cancer vaccines are moving from a niche immuno-oncology concept to a strategic pillar of cancer prevention and treatment. The category includes proven preventive vaccines, such as human papillomavirus and hepatitis B vaccines, as well as therapeutic platforms designed to activate tumor-specific immune responses using neoantigens, peptides, dendritic cells, viral vectors, or mRNA.

The need is substantial: the International Agency for Research on Cancer estimated 20.0 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with more than 35 million new cases projected by 2050. This burden is accelerating investment in cancer vaccine development, combination immunotherapy, biomarker-led clinical trials, and scalable manufacturing models.

Transformative Shifts in the Cancer Vaccine Landscape

The cancer vaccines landscape is being reshaped by precision oncology, rapid sequencing, and the clinical validation of immunotherapy combinations. Development priorities are shifting from standardized tumor-associated antigen approaches toward personalized neoantigen vaccines tailored to each patient’s tumor mutations and HLA profile.

At the same time, mRNA vaccine infrastructure built during the COVID-19 era has improved confidence in rapid design, production, and clinical deployment. Market participants are also prioritizing checkpoint inhibitor combinations, earlier-line treatment settings, and measurable residual disease strategies to improve response durability and demonstrate health-economic value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative advantage across the cancer vaccine value chain. AI models are increasingly used to predict neoantigen immunogenicity, evaluate HLA binding, analyze multi-omics datasets, identify patient subgroups, and optimize trial enrollment. These capabilities can shorten discovery timelines and improve the probability that selected antigens generate clinically meaningful immune responses.

AI is also strengthening manufacturing analytics, quality control, pharmacovigilance, and real-world evidence generation. However, industry leaders must pair AI-enabled speed with validated datasets, transparent model governance, regulatory documentation, and clinically interpretable outputs to support FDA, EMA, and other agency expectations.

Key Regional Insights for Cancer Vaccines

North America remains a leading region for cancer vaccine innovation due to deep oncology research networks, NCI-supported programs, FDA experience with immunotherapy regulation, and strong venture funding. The United States and Canada also benefit from high use of genomic testing, established clinical trial infrastructure, and broad adoption of immune checkpoint inhibitors, creating a favorable environment for therapeutic cancer vaccine combinations. Europe benefits from established cancer centers, EMA oversight, Horizon Europe research funding, and growing interest in advanced therapy manufacturing, although pricing, reimbursement, and health technology assessment requirements influence adoption across the European Union, the United Kingdom, and other European markets.

Asia-Pacific is expanding through China’s clinical trial scale, Japan’s regenerative medicine frameworks, South Korea’s biologics capabilities, Australia’s oncology trial ecosystem, and India’s vaccine manufacturing base. The region also has major relevance for preventive cancer vaccines because WHO and national immunization programs continue to emphasize HPV vaccination for cervical cancer prevention and hepatitis B vaccination for liver cancer prevention. Latin America, the Middle East, and Africa present rising long-term demand driven by cervical, liver, and other infection-associated cancers. In Latin America, public immunization programs and oncology trial participation support access pathways, while the Middle East is investing in precision medicine, national genomics, and specialist cancer centers. Africa has a high need for preventive vaccination and early cancer detection, but access, cold-chain capacity, reimbursement, oncology workforce availability, and genomic infrastructure remain decisive constraints.

Key Group Insights Across Major Economic Blocs

Within ASEAN, cancer vaccine opportunities are linked to HPV vaccination expansion, regional trial participation, rising cancer screening initiatives, and growing biologics manufacturing ambition in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is investing in precision medicine, national genomics, digital health records, and specialized cancer centers, positioning the group as a selective adopter of advanced immuno-oncology technologies and companion diagnostic-enabled cancer vaccine programs.

The European Union supports translational research, cross-border clinical development, regulatory standardization, and centralized evaluation of novel immunotherapies, while BRICS countries offer large patient populations, cost-efficient clinical development, and expanding biomanufacturing capacity across China, India, Brazil, Russia, and South Africa. G7 markets continue to shape reimbursement evidence, intellectual property standards, clinical trial quality, and regulatory expectations for personalized cancer vaccines. NATO member markets are also relevant through resilient supply chain planning, biosecurity priorities, cold-chain reliability, cross-border medical innovation networks, and coordinated preparedness for advanced biologics manufacturing.

Key Country Insights for Priority Cancer Vaccine Markets

The United States leads in cancer vaccine clinical trials, venture funding, FDA precedent, and academic-industry partnerships, while Canada contributes strong oncology research, population health datasets, and real-world evidence capabilities. Mexico and Brazil offer important Latin American trial access and public-health relevance for infection-related cancers, particularly cervical and liver cancer prevention. The United Kingdom, Germany, France, Italy, and Spain combine advanced cancer centers, genomic medicine programs, and mature regulatory pathways with evolving reimbursement scrutiny, while Russia remains scientifically active but affected by geopolitical, funding, and access constraints.

China is rapidly scaling domestic immuno-oncology pipelines, clinical trial enrollment, sequencing capacity, and biologics manufacturing. India combines high disease burden with large-scale vaccine manufacturing strength, expanding digital health infrastructure, and increasing oncology trial participation. Japan supports advanced therapies through mature regulation, strong translational science, and established oncology care pathways. Australia is a favored early-phase oncology trial hub due to efficient trial start-up processes, high-quality clinical sites, and diverse patient recruitment opportunities. South Korea is gaining visibility through biologics manufacturing, digital health infrastructure, national cancer screening experience, and precision oncology investment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that demonstrate clear biological rationale, reproducible immune activation, and compatibility with combination regimens. Programs should be designed around validated biomarkers, robust companion diagnostics, and patient-selection strategies that can support regulatory review, clinical utility assessment, and payer acceptance.

Commercial readiness requires investment in sequencing logistics, individualized manufacturing capacity, cold-chain control, decentralized clinical workflows, and quality systems aligned with advanced biologics requirements. Organizations should also pursue partnerships with cancer centers, genomic testing providers, CDMOs, clinical research networks, and public-health organizations to improve trial speed, manufacturing reliability, equitable access, and evidence generation across diverse populations.

Research Methodology

This executive summary is based on triangulated secondary research and industry analysis using publicly available information from authoritative sources, including the WHO, IARC, FDA, EMA, ClinicalTrials.gov, peer-reviewed oncology journals, public regulatory documents, and major cancer research organizations.

The methodology emphasizes verified epidemiology, regulatory precedent, clinical development activity, technology trends, preventive vaccination evidence, and regional healthcare infrastructure. Insights were assessed for relevance to cancer vaccine commercialization, therapeutic development, preventive vaccination, manufacturing scalability, reimbursement readiness, regulatory feasibility, and competitive positioning across mature and emerging markets.

Conclusion

Cancer vaccines are entering a more commercially relevant phase as oncology shifts toward earlier intervention, personalized immunotherapy, and durable immune control. Preventive vaccination already provides proven cancer-reduction value, while therapeutic vaccine pipelines are becoming more sophisticated through mRNA platforms, neoantigen science, viral vectors, dendritic cell approaches, and AI-enabled antigen selection.

The strongest opportunities will favor organizations that combine clinical rigor with manufacturing agility, regulatory discipline, data infrastructure, and access planning. As cancer incidence rises globally, cancer vaccines are positioned to become an increasingly important component of precision oncology and population-level cancer prevention.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Vaccines Market, by Product Type
7.1. Introduction
7.2. Preventive Cancer Vaccines
7.3. Therapeutic Cancer Vaccines
8. Cancer Vaccines Market, by Formulations
8.1. Introduction
8.2. Cell-Based Vaccines
8.2.1. Dendritic Cell Vaccines
8.2.2. Tumor Cell Vaccines
8.3. Nucleic Acid-Based Vaccines
8.3.1. DNA Vaccines
8.3.2. RNA Vaccines
8.4. Peptide/Protein-Based Vaccines
8.5. Synthetic Vaccines
8.6. Viral Vector-Based Vaccines
9. Cancer Vaccines Market, by Route Of Administration
9.1. Introduction
9.2. Intradermal
9.3. Subcutaneous
9.4. Intramuscular
9.5. Intravenous
10. Cancer Vaccines Market, by Treatment Strategy
10.1. Introduction
10.2. Monotherapy
10.3. Combination Therapy
11. Cancer Vaccines Market, by Disease Stage
11.1. Introduction
11.2. Early Stage
11.3. Locally Advanced
11.4. Metastatic
11.5. Recurrent Or Relapsed
12. Cancer Vaccines Market, by Indication
12.1. Introduction
12.2. Solid Tumors
12.2.1. Prostate Cancer
12.2.2. Cervical Cancer
12.2.3. Lung Cancer
12.2.4. Melanoma
12.2.5. Breast Cancer
12.2.6. Colorectal Cancer
12.2.7. Ovarian Cancer
12.2.8. Bladder Cancer
12.2.9. Head & Neck Cancer
12.3. Hematologic Malignancies
12.3.1. Leukemia
12.3.2. Lymphoma
12.3.3. Multiple Myeloma
13. Cancer Vaccines Market, by End-User
13.1. Introduction
13.2. Cancer Research Institutes
13.3. Hospitals & Clinics
13.4. Specialty Cancer Treatment Centers
14. Cancer Vaccines Market, by Region
14.1. North America
14.2. Europe
14.3. Asia-Pacific
14.4. Latin America
14.5. Middle East
14.6. Africa
15. Cancer Vaccines Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Cancer Vaccines Market, by Country
16.1. United States
16.2. Germany
16.3. United Kingdom
16.4. China
16.5. India
16.6. Japan
16.7. France
16.8. South Korea
16.9. Canada
16.10. Brazil
16.11. Mexico
16.12. Australia
16.13. Italy
16.14. Spain
16.15. Russia
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Merck & Co., Inc.
18.2. GSK PLC
18.3. Dynavax Technologies Corporation
18.4. Serum Institute of India Pvt. Ltd.
18.5. Dendreon Pharmaceuticals LLC
18.6. JW CreaGene
18.7. Amgen Inc.
18.8. AstraZeneca PLC
18.9. BioNTech SE
18.10. Bristol Myers Squibb Company
18.11. Celldex Therapeutics, Inc.
18.12. CureVac SE
18.13. Eli Lilly and Company
18.14. F. Hoffmann-La Roche AG
18.15. Ferring B.V.
18.16. Helsinn Healthcare SA
18.17. Inovio Pharmaceuticals, Inc.
18.18. Johnson & Johnson Services, Inc
18.19. Moderna, Inc.
18.20. OS Therapies
18.21. Pfizer Inc.
18.22. Sanofi SA
18.23. Sun Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL CANCER VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER VACCINES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANCER VACCINES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANCER VACCINES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CANCER VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PREVENTIVE CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PREVENTIVE CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PREVENTIVE CANCER VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL THERAPEUTIC CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL THERAPEUTIC CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL THERAPEUTIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TUMOR CELL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TUMOR CELL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL TUMOR CELL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DNA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL DNA VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL DNA VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL RNA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL RNA VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL RNA VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PEPTIDE/PROTEIN-BASED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PEPTIDE/PROTEIN-BASED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PEPTIDE/PROTEIN-BASED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SYNTHETIC VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SYNTHETIC VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL VIRAL VECTOR-BASED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL VIRAL VECTOR-BASED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL VIRAL VECTOR-BASED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL EARLY STAGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL EARLY STAGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL EARLY STAGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LOCALLY ADVANCED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LOCALLY ADVANCED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LOCALLY ADVANCED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL METASTATIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL METASTATIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL METASTATIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RECURRENT OR RELAPSED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RECURRENT OR RELAPSED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RECURRENT OR RELAPSED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CERVICAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CERVICAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CERVICAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL BLADDER CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL BLADDER CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL BLADDER CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HEAD & NECK CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HEAD & NECK CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL HEAD & NECK CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL SPECIALTY CANCER TREATMENT CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL SPECIALTY CANCER TREATMENT CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL SPECIALTY CANCER TREATMENT CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 137. EUROPE CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. EUROPE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 139. EUROPE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 140. EUROPE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 141. EUROPE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 142. EUROPE CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 143. EUROPE CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 144. EUROPE CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 145. EUROPE CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 146. EUROPE CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 147. EUROPE CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 148. EUROPE CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 185. AFRICA CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 186. AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 187. AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 188. AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 189. AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 190. AFRICA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 191. AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 192. AFRICA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 193. AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 194. AFRICA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 195. AFRICA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 196. AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. NATO CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. NATO CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 200. NATO CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 201. NATO CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 202. NATO CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 203. NATO CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. NATO CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 205. NATO CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 206. NATO CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 207. NATO CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 208. NATO CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 209. NATO CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 210. G7 CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. G7 CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 212. G7 CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 213. G7 CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 214. G7 CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 215. G7 CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 216. G7 CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 217. G7 CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 218. G7 CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 219. G7 CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 220. G7 CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 221. G7 CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 234. BRICS CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 235. BRICS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 236. BRICS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 237. BRICS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 238. BRICS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 239. BRICS CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 240. BRICS CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 241. BRICS CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 242. BRICS CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 243. BRICS CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 244. BRICS CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 245. BRICS CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 246. ASEAN CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 247. ASEAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 248. ASEAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 249. ASEAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 250. ASEAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 251. ASEAN CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. ASEAN CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 253. ASEAN CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 254. ASEAN CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 255. ASEAN CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 256. ASEAN CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 257. ASEAN CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 258. GCC CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 259. GCC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 260. GCC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 261. GCC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 262. GCC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 263. GCC CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 264. GCC CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 265. GCC CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 266. GCC CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 267. GCC CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 268. GCC CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 269. GCC CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 270. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 283. GERMANY CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 284. GERMANY CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 285. GERMANY CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 286. GERMANY CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 287. GERMANY CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 288. GERMANY CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 289. GERMANY CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 290. GERMANY CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 291. GERMANY CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 292. GERMANY CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 293. GERMANY CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 294. GERMANY CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 297. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 298. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 301. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 307. CHINA CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. CHINA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 309. CHINA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 310. CHINA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 311. CHINA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 312. CHINA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 313. CHINA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 314. CHINA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 315. CHINA CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 316. CHINA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 317. CHINA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 318. CHINA CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 319. INDIA CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. INDIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 321. INDIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 322. INDIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 323. INDIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 324. INDIA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 325. INDIA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 326. INDIA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 327. INDIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 328. INDIA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 329. INDIA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 330. INDIA CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 331. JAPAN CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 332. JAPAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 333. JAPAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 334. JAPAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 335. JAPAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 336. JAPAN CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 337. JAPAN CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 338. JAPAN CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 339. JAPAN CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 340. JAPAN CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 341. JAPAN CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 342. JAPAN CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 343. FRANCE CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 344. FRANCE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 345. FRANCE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 346. FRANCE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 347. FRANCE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 348. FRANCE CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 349. FRANCE CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 350. FRANCE CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 351. FRANCE CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 352. FRANCE CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 353. FRANCE CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 354. FRANCE CANCER VACCINES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA CANCER VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 356. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 357. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 358. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 359. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2017-2032 (USD MILLION)
TABLE 360. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2017-2032 (USD MILLION)
TABLE 362. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 363. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 364. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 365. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 366. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY END-USER, 20

Companies Mentioned

  • Merck & Co., Inc.
  • GSK PLC
  • Dynavax Technologies Corporation
  • Serum Institute of India Pvt. Ltd.
  • Dendreon Pharmaceuticals LLC
  • JW CreaGene
  • Amgen Inc.
  • AstraZeneca PLC
  • BioNTech SE
  • Bristol Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • CureVac SE
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring B.V.
  • Helsinn Healthcare SA
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc
  • Moderna, Inc.
  • OS Therapies
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 11.55 Billion
Forecasted Market Value ( USD ) by 2032 $ 21.28 Billion
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Cancer Vaccines Market by Type, Technology, Indication, ROA, End User - Global Forecast to 2032 - Product Image

Cancer Vaccines Market by Type, Technology, Indication, ROA, End User - Global Forecast to 2032

  • Report
  • 263 Pages
  • Global
From
US cancer vaccine industry outlook to 2028 - Product Image

US cancer vaccine industry outlook to 2028

  • Report
  • 85 Pages
  • United States
From
Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence - Product Image

Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence

  • Directory
  • Global
From
Dendritic Cell Cancer Vaccine Market - Global Forecast 2026-2032 - Product Image

Dendritic Cell Cancer Vaccine Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Neoantigen Cancer Vaccine Market - Global Forecast 2026-2032 - Product Image

Neoantigen Cancer Vaccine Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.